2-drug blood pressure therapy lowers cardiovascular risk

Mar 31, 2008

An international blood pressure study comparing two single-pill drug combinations has yielded results so significant that the study has been stopped early – and the researchers say their findings might alter the way high blood pressure is treated worldwide.

The randomized study showed that both drug combinations helped people who had high blood pressure and other cardiovascular risk factors get their BP down to recommended levels – despite the fact that two-thirds of them had been unable to achieve good BP control with other medications before they entered the study.

But even more important, the study revealed that the patients taking one of the combinations had 20 percent fewer heart-related events than the patients taking the other one. Those events included cardiovascular deaths, heart attacks, strokes, hospitalizations for unstable angina and treatments to re-open blocked heart arteries.

In all, 10,700 study participants took a single tablet that includes two medications. One group received a tablet containing benazepril, which is a type of drug called an ACE inhibitor, and amlodipine, which belongs to a class of drugs known as calcium channel blockers or CCBs. The other pill combined benazepril and hydrochloro-thiazide, a type of diuretic or “water pill.” The 20 percent reduction in cardiovascular events was observed with the ACE/CCB combination tablet.

Currently, national guidelines for the treatment of high blood pressure (also called hypertension) call for patients who need medication to start out on a single pill, usually a diuretic, and to add other drugs only as needed to bring pressure down. But the new results, presented today at the American College of Cardiology Scientific Session in Chicago, may signal a need to change those guidelines.

“These results demonstrate the superiority of an ACE/CCB pill fixed-dose combination treatment strategy for reducing cardiovascular morbidity and mortality, and provides evidence that should modify future guidelines for the treatment of hypertension,” says Kenneth Jamerson, M.D., the leader of the study, which is called ACCOMPLISH. Jamerson is a professor of internal medicine at the University of Michigan Medical School and a member of the U-M Cardiovascular Center.

The study was funded by Novartis, which is among the companies that offer two-drug combination tablets for blood pressure treatment.

Millions of Americans take medications for hypertension but do not achieve control of their blood pressure. Single-tablet combinations of drugs are seen as easier for patients to take than multiple pills.

Results from the ACCOMPLISH trial show that just six months of treatment with either drug combination was enough to bring the blood pressure of 73 percent of patients into an acceptable range.

However, by the end of the trial blood pressure control rates were 80 percent, with mean systolic blood pressure less than 130 mmHg. This represents exceptional blood pressure control when contrasted to the current control rate of approximately 30 percent in the United States.

All patients in the study received no more than 40 milligrams of benazepril in each dose; amlodipine doses began at 5 mg and could be increased to 10 mg, while hydrochlorothiazide doses began at 12.5 mg and could be increased to 25 mg.

Many studies have already shown that reducing blood pressure can reduce the risk of stroke, heart attack, heart failure and other conditions, but many people have a very difficult time achieving blood pressure control.

“These ACCOMPLISH results shake the foundations of current recommendations and define a new standard which will enhance the achievement of the primary goal and assist clinicians in meeting the daily challenges of hypertension management,” says ACCOMPLISH executive committee member Eric J. Velazquez, M.D., an Associate Professor of Medicine at Duke University Medical Center.

Currently, blood pressure treatment guidelines call for a single medicine to be tried first in people with Stage 1 hypertension -- those with the top, or systolic, reading over 140 and the bottom, or diastolic, reading over 90, but with readings less than 160 systolic and 100 diastolic.

As many as 73 million Americans have high blood pressure. But because high BP doesn’t cause symptoms, most people who have it don’t know they have it. Over time, uncontrolled blood pressure affects the blood vessel walls, encouraging the growth of weak spots called aneurysms and the formation of narrowed and inflamed areas that can lead to clots that can break off and cause heart attacks and strokes.

Fortunately, once the condition is diagnosed, doctors have a broad range of medicines to choose from to try to get it under control, including many inexpensive generic medicines.

But studies have found that patients often have trouble taking the multiple medications they need. As a result, many companies have developed combination pills. The ACCOMPLISH data suggest these combination tablets have the potential to improve control rates to over 80 percent and importantly, that the combination of ACE and CCB reduced cardiovascular events by 20% when compared to the diuretic statedgy.

Source: University of Michigan

Explore further: Over-the-counter pain reliever may restore immune function in old age

add to favorites email to friend print save as pdf

Related Stories

New particle-sorting method breaks speed records

Jun 24, 2014

Researchers compare the processing of biological fluid samples with searching for a needle in a haystack—only in this case, the haystack could be diagnostic samples, and the needle might be tumor cells ...

The promise and risks of big data

May 30, 2014

To its proponents, big data offers a big promise: insight into complex—and critically important—questions in health care, science, business and more. But its detractors say it poses big risks for individual ...

Identical twins offer up selves for space science

May 28, 2014

Astronauts Scott and Mark Kelly will take part in an unprecedented study of identical twins to better understand the effects of prolonged weightlessness by comparing the twin in space with the twin on the ...

Recommended for you

Gamers helping in Ebola research

22 hours ago

Months before the recent Ebola outbreak erupted in Western Africa, killing more than a thousand people, scientists at the University of Washington's Institute for Protein Design were looking for a way to stop the deadly virus.

Carcinogenic role of a protein in liver decoded

Sep 01, 2014

The human protein EGFR controls cell growth. It has mutated in case of many cancer cells or exists in excessive numbers. For this reason it serves as a point of attack for target-oriented therapies. A study ...

User comments : 0